| |
Market and value analysis positions neurotech startup for successful U.S. product commercialization and adoption. Learn how. .png)
|
|
Today's Big NewsJun 20, 2023 |
| By Angus Liu When Nurtec ODT started steaming ahead in 2021, Eli Lilly sought to blunt the oral rival’s momentum with a trial designed to show its injectable Emgality works better at preventing migraines. That project has now fallen through. |
|
|
|
| Free Virtual Event |  |
|
|
By Nick Paul Taylor Gilead Sciences' $225 million bet on Arcellx’s CAR-T cell therapy has hit turbulence. Months after Arcellx closed the deal, the FDA has put a pivotal trial of the anti-BCMA therapy on hold in response to the death of a patient. |
By Andrea Park BD announced Tuesday that it has inked a deal with Steris, an Irish maker of medical equipment used for sterilization and surgical procedures, to sell off its surgical instrumentation unit. |
By Angus Liu The largest multinational pharma company in China has reportedly made plans to separate its local business in case geopolitical tensions worsen. But the company is hitting back at the recent news report. |
|
Wednesday, July 12, 2023 | 2pm ET / 11am PT In this webinar, we will explore how critical it is for life sciences companies to use data to analyze the behavior of cancer at the individual level, uncover new targets and biomarkers for precision therapies, and increase the value of existing oncology drugs to new indications. Register now. 
|
|
By James Waldron Eli Lilly has taken a high-stakes gamble on oral IL-17 inhibitors, betting $2.4 billion upfront that acquiring Dice Therapeutics will expand its autoimmune arsenal. |
By Kevin Dunleavy An International Chamber of Commerce arbitration tribunal has sided with Sanofi, rejecting Boehringer Ingelheim's attempt to receive liability protections for cancer claims in the United States tied to heartburn medicine Zantac. In an asset swap with Boehringer in 2016, Sanofi gained U.S. marketing rights to the treatment. |
By Andrea Park After a mix of skyrocketing expenses and dwindling cash stores led Surgalign late last year to kick off a companywide review of additional cost-cutting options, the surgical device maker has settled on selling off the entire business. |
By Angus Liu Immune checkpoint inhibitors haven’t had tons of success in stomach cancer. Now, Merck has added one failure to the mix. |
By Ben Adams Boris Johnson, who around a year ago was forced out as Prime Minister of the U.K. and now this month has left the British government entirely, has picked up the pen once again in a new role for the Daily Mail. |
By James Waldron Two months after dropping one of its GLP-1 agonists, AstraZeneca has decided to scrap its remaining clinical candidate. A preliminary analysis of the phase 1 data convinced the company that the drug would not outperform the competition. |
By Kevin Dunleavy In the battle for diabetes and obesity superiority, Novo Nordisk holds a head start as the original developer of the metabolism-regulating treatment semaglutide. But Eli Lilly is quickly gaining ground and is primed to become the market leader with its GLP-1 treatment Mounjaro, according to GlobalData. |
By Ben Adams Eli Lilly has had a tough time on insulin pricing: It’s long been under fire, like many of its peers, over the high cost of the diabetes therapy, and last year was also hit by a Twitter spoof about making insulin free that saw its stock price tank. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss the the top news from this year's annual BIO meeting, plus a COVID lawsuit, an FDA-approved app and the rest of the week's headlines. |
|
|---|
|
|
|
Wednesday, July 12, 2023 | 11am ET / 8am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now. 
|
|
Whitepaper Autoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
eBook See how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
Whitepaper This paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
